Paget's disease of bone Eating disorders Hunger Tay-Sachs Alzheimer Osteogenesis imperfecta Psoriasis Hair Loss Tailbone Kwashiorkor Filariasis Turner syndrome

Risk of thrombosis in patients with essential thrombocythemia and ...

Source: www.haematologica.org
Topic: Polycythemia Vera
Download: Click here!

Sort Desciption: Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status Letters to the Editor haematologica/the hematology journal ...

Content Inside:
Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status Letters to the Editor haematologica/the hematology journal 2007; 92(01) 135 Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status We compared the laboratory and clinical findings of 179 patients with essential thrombocythemia (ET) and 77 with polycythemia vera (PV) classified according to the presence of the JAK2 V617F mutation. A gradient between patients with JAK2 wildtype ET, JAK2 V617F ET and PV (all carrying the JAK2 mutation) was observed. The rate of thrombotic complications in JAK2-positive ET was significantly higher than in wild-type ET and not statistically different from that of PV patients. Haematologica 2007; 92:135-136 The presence of the JAK2 V617F mutation divides essential thrombocythemia (ET) into two distinct subtypes. Patients with the mutation present higher hemoglobin levels, higher white cell counts and bone marrow hypercellularity. 1,4 An increased risk of thrombosis in mutated ET patients has been also reported by some investigators, 1,2 but not by others. 3,4 These observations have generated the hypothesis of a possible biological continuum between ET and polycythemia vera (PV). 1 This interesting view would be further supported if the clinical vascular complications of JAK2 mutated ET were comparable to those of PV patients. At the best of out knowledge, a direct comparison between the thrombotic risk of patients with ET, stratified by JAK2 V617F status, and those with PV was not hitherto reported. To tackle this issue, we evaluated the laboratory findings at presentation and the clinical complications at diagnosis and during follow-up in two parallel cohorts of 179 ET and 77 PV patients, regularly followed in our outpatient clinic, and classified according to the presence of the JAK2 V617F mutation. The following statistical analysis were ...

Name (required)

E-mail (required - never shown publicly)

URI (optional)

Your Comment

Verification Code

© 2007-2009 HealthPDF.org | Design by Ganesh Gunasegaran
Privacy Policy

All files and contents mentioned are the property of their respective owners. This page consists of a compilation of public information, commonly available on the internet, at multiple sites, as well as official websites. No information on this page is guaranteed to be correct, and any data contained here may be erroneous.